Quick Answer
COLLEGIUM PHARMACEUTICAL, INC reported Operating Income Loss of $179.64 million for the year ending 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +5.7% in Operating Income Loss from 2024 to 2025.
- This data is from COLLEGIUM PHARMACEUTICAL, INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: -$9.44 million | Q1 2016: -$15.59 million | Q2 2016: -$24.47 million | Q3 2016: -$26.44 million | Q4 2016: -$27.58 million | Q1 2017: -$23.18 million | Q2 2017: -$21.26 million | Q3 2017: -$13.43 million | Q4 2017: -$17.58 million | Q1 2018: -$13.21 million | Q2 2018: -$7.29 million | Q3 2018: -$11.19 million | Q4 2018: $11.00 million | Q1 2019: -$9.99 million | Q2 2019: -$5.01 million | Q3 2019: -$6.38 million | Q4 2019: -$2.37 million | Q1 2020: $5.06 million | Q2 2020: $16.55 million | Q3 2020: $19.63 million | Q4 2020: $15.00 million | Q1 2021: $21.19 million | Q2 2021: $16.41 million | Q3 2021: $14.15 million | Q4 2021: -$34.12 million | Q1 2022: -$10.02 million | Q2 2022: $11.11 million | Q3 2022: $20.47 million | Q4 2022: $11.76 million | Q1 2023: $24.63 million | Q2 2023: $35.63 million | Q3 2023: $45.01 million | Q4 2023: $61.69 million | Q1 2024: $49.47 million | Q2 2024: $47.47 million | Q3 2024: $34.84 million | Q4 2024: $38.11 million | Q1 2025: $21.69 million | Q2 2025: $35.11 million | Q3 2025: $62.09 million | Q4 2025: $60.76 million.
- Over the full 13 years of available data (2013 to 2025), COLLEGIUM PHARMACEUTICAL, INC's Operating Income Loss has grown by 1,219.8%.
- Historical annual values: Fiscal year 2025: $179.64 million | Fiscal year 2024: $169.90 million | Fiscal year 2023: $166.96 million | Fiscal year 2022: $33.32 million | Fiscal year 2021: $17.63 million | Fiscal year 2020: $56.23 million | Fiscal year 2019: -$23.75 million | Fiscal year 2018: -$20.69 million | Fiscal year 2017: -$75.45 million | Fiscal year 2016: -$94.08 million | Fiscal year 2015: -$26.91 million | Fiscal year 2014: -$17.67 million | Fiscal year 2013: -$16.04 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: